

CStone, Pfizer address oncological needs in China

30 September 2020 | News

Pfizer to invest \$200 million in CStone shares and license CStone's late-stage oncology asset sugemalimab (CS1001, PD-L1 antibody) in mainland China

CStone Pharmaceuticals, headquartered in China and Pfizer Investment Co. Ltd. and Pfizer Corporation Hong Kong Limited (both of which are subsidiaries of Pfizer Inc.) have announced the formation of a strategic collaboration that encompasses a \$200 million equity investment by Pfizer Hong Kong in CStone, collaboration between CStone and Pfizer Investment for the development and commercialization of CStone's sugemalimab (CS1001, PD-L1 antibody) in mainland China, and a framework between CStone and Pfizer Investment to bring additional oncology assets to the Greater China market.

This collaboration provides financing to support CStone's development of sugemalimab, a potential best-in-class PD-L1 antibody that is being developed for high-incidence cancer indications in China, including lung, gastric and esophageal cancers, among others.

Pfizer will in-license and exclusively lead commercialization of sugemalimab in China, harnessing its industry-leading capabilities to help doctors and patients across a far wider range of regions gain greater access to this treatment.

The collaboration positions CStone and Pfizer to develop and commercialize additional oncology assets for the Greater China market.